A further series of executive changes at Alexion Pharmaceuticals Inc. has been cautiously welcomed as an opportunity for recently appointed new CEO Ludwig Hantson to build his own team and have a complete break from past company missteps, but observers are questioning whether the changes are sufficient to boost confidence in the US company.
The ultra-rare disease drug developer was rocked by a sales audit investigation at the end of last year - that...





